Maklumat tambahan indikasi untuk upload pada laman web
Year 2016
Products Approved For Additional Indication (DCA 304 – 27 September 2016)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 **HUMIRA SOLUTION FOR INJECTION** [Adalimumab 40mg/0.8 ml]	➢ Indication: *Axial Spondyloarthritis:* *Ankylosing Spondylitis* *Humira is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.* *Non-radiographic Axial Spondyloarthritis (Axial Spondyloarthritis without Radiographic Evidence of AS)* *Humira is indicated for reducing signs and symptoms in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.* ➢ Posology: *Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis (Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis)* *The recommended dose of Humira of adult patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) is 40mg administered every other week as a single dose via subcutaneous injection. Methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, analgesics or other DMARDs may be continued during treatment with Humira.* *In rheumatoid arthritis, some patients not taking concomitant MTX may derive additional benefit from increasing the dosing frequency of Humira to 40 mg every week. (optional)*	**ABBVIE SDN BHD** 9th Floor Menara Lien Hoe No.8, Persiaran Tropicana Tropicana Golf & Country Resort 47410 Petaling Jaya, Selangor